The development, commercialization, and utilization of drug combinations have skyrocketed in the United States. According
to PharmaCircle research, the number of fixed dose combinations (FDC) approvals has more than tripled over the last decade
compared to the early 1990s. Currently, there are numerous marketed FDCs and other combination regimens spanning multiple
therapeutic areas, including infectious disease (HIV/AIDS, Hepatitis C, bacterial infections); oncology; endocrine disorders
(diabetes, lipids); cardiovascular disease (hypertension, heart failure); women's health (contraception, menopause, osteoporosis);
and respiratory diseases (asthma, COPD). According to an Oliver Wyman analysis, there were over 25 notable novel combination
development programs underway in oncology alone in 2011.
Stan Bernard, MD, MBA
Several factors have driven the dramatic escalation of combination products over the last decade:
Greater scientific understanding. Recent scientific advances have enhanced our understanding of the pathophysiology of HIV, cancer, and other complex diseases.
Highly active antiretroviral therapy (HAART)—the use of at least three HIV drugs acting on different viral targets—reduces
HIV replication, viral resistance, patient mortality, and morbidity rates while improving quality of life. Similarly, increasing
recognition that most cancers use multiple pathways to grow and proliferate has spurned development of entirely new classes
of oncology agents, such as immunotherapies and targeted therapies, which are being combined to inhibit distinct pathway targets
in order to improve treatment response while minimizing tumor resistance and side effects.
Supportive regulatory and clinical environment. Historically, the FDA and the US medical community were skeptical about drug combinations. However, regulatory policies and
clinical thinking have dramatically changed over the last decade. The FDA established the "Office of Combination Products"
in 2002 to evaluate combinations of drugs with other medicine products, such as devices and biologics. In 2004, the US government
announced an expedited pathway for the FDA to review low-fixed dose combinations, co-packaged therapies, and single-ingredient
HIV therapies for use by grant recipients of the US President's Emergency Plan for AIDS Relief. This past June, the FDA issued
guidance for the "co-development of two or more new investigational drugs for use in combination" to address the rising number
of novel combinations.
Addressing public health threats. FDCs are critically important for managing global infectious disease threats such as HIV/AIDS, malaria, and tuberculosis.
The World Health Organization and other public health entities have encouraged the development of fixed-dose combinations
which may improve adherence, reduce costs, and facilitate distribution in developing countries.
Product differentiation opportunities. With increasing brand competition, companies are eager to demonstrate better efficacy, safety, and convenience using a combination
which is synergistic or additive. Companies competing in HIV, asthma/COPD, and diabetes have demonstrated higher efficacy
rates with combinations versus single agents.
Increased utilization. Companies are pairing second- and third-line drugs with first-line products to enhance market access, earlier use, or preferred
utilization. For example, many companies have combined their diabetes type 2 agents with first-line metformin, including Merck's
combination of its best-selling brand Januvia with metformin to create Janumet.
Leveraging the portfolio. Companies increasingly are adopting a "multi-level competition" approach where they seek to win not only with a single brand
but also across their product franchises and portfolios. Gilead Sciences wants to maximize sales of multiple HIV products
to enhance its HIV franchise as well as with its new Hepatitis C (HCV) products to win with its overall anti-viral portfolio.
Similarly, Roche bolsters sales of individual brands and its overall oncology portfolio by encouraging the use of combination
regimens of its cancer agents.
Extending the patent life. Industry critics note that companies combine drugs nearing patent expiry with newer drugs with longer patents to extend the
proprietary rights and marketability of the older agent. Some believe that Pfizer was using this "evergreening" strategy in
its failed attempt to develop its powerful HDL-raising developmental agent torcetrapib only in combination with its best-selling,
near patent-expiration agent Lipitor, instead of as developing it as monotherapy.
Combination drugs can be classified into two general categories: "combination drugs," consisting of drug-drug combinations;
and "combination products," consisting of drug/non-drug combinations. A combination drug most commonly refers to a fixed-dose combination, a formulation including two or more active pharmaceutical ingredients combined
in a single dosage form. However, companies may promote drug combination regimens which are not necessarily fixed dosed, such
as co-packaged products or "free combinations," two or more medicines with separate formulations and specific labeling for
simultaneous use. Initially, fixed-dose combination drug products were developed primarily to target a single disease, such
as Gilead's anti-HIV FDCs. However, some FDCs target multiple diseases or conditions. For example, Pfizer's Caduet is a FDC
containing Lipitor to treat hypercholesterolemia and Norvasc to treat hypertension.
The FDA defines combination products as those which "combine different types of medical products, such as drug/device, biologic/device, drug/biologic, or drug/device/biologic,
that are physically, chemically, or otherwise combined or mixed and produced as a single entity." Examples of combination
products include a monoclonal antibody combined with a therapeutic drug; a device coated or impregnated with a drug or biologic
such as a drug-eluting stent; an orthopedic implant with growth factors; or insulin injector pens and metered dose inhalers.